Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;157–60.
Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, et al. Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis. 2021;72:e695–703.
Rosner CM, Genovese L, Tehrani BN, Atkins M, Bakhshi H, Chaudhri S, et al. Myocarditis temporally associated with COVID-19 vaccination. Circulation. 2021;502–5.
Larson KF, Ammirati E, Adler ED, Cooper LT, Hong KN, Saponara G, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. Circulation. 2021;144:506–8.
Abu Mouch S, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39:3790–3.
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092–101.
Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124–30.
Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2202–11.
Sessa F, Salerno M, Esposito M, Di Nunno N, Zamboni P, Pomara C. Autopsy findings and causality relationship between death and COVID-19 vaccination: a systematic review. J Clin Med. 2021;10.
Cines DB, Bussel JB. SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254–6.
Xie C, Vincent L, Chadwick A, Peschl H. COVID-19 vaccine induced prothrombotic immune thrombocytopenia. Eur Heart J. 2021;42:3206.
Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med. 2021;49:58–61.
MacNeil JR, Su JR, Broder KR, Guh AY, Gargano JW, Wallace M, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients — United States, April 2021. MMWR Recomm Reports. 2021;70:1–6.
Baker AT, Boyd RJ, Sarkar D, Teijeira-Crespo A, Chan CK, Bates E, et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Sci Adv. 2021;7:8213.
Novak N, Tordesillas L, Cabanillas B. Adverse rare events to vaccines for COVID-19: From hypersensitivity reactions to thrombosis and thrombocytopenia. Int Rev Immunol. 2021;41:1–10.
Cari L, Fiore P, Naghavi Alhosseini M, Sava G, Nocentini G. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. J Autoimmun. 2021;122:102685.
Chen P-W, Tsai Z-Y, Chao T-H, Li Y-H, Hou CJ-Y, Liu P-Y. Addressing vaccine-induced immune thrombotic thrombocytopenia (VITT) following COVID-19 vaccination: a mini-review of practical strategies. Acta Cardiol Sin. 2021;37:355–64.
Schulz JB, Berlit P, Diener HC, Gerloff C, Greinacher A, Klein C, et al. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol. 2021;90:627–39.
Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127:834–9.
Neame PB, Lechago J, Ling ET, Koval A. Thrombotic thrombocytopenic purpura: report of a case with disseminated intravascular platelet aggregation. Blood. 1973;42:805–14.
Kwaan HC. Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol. 1987;24:71–81.
Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985;38:469–79.
Tasaki T, Yamada S, Nabeshima A, Noguchi H, Nawata A, Hisaoka M, et al. An autopsy case of myocardial infarction due to idiopathic thrombotic thrombocytopenic purpura. Diagn Pathol. 2015;10:52.
Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13:300–17.
Watanabe T, Imamura T, Nakagaki K, Tanaka K. Disseminated intravascular coagulation in autopsy cases its incidence and clinicopathologic significance. Pathol Res Pract Gustav Fischer Verlag. 1979;165:311–22.
Ohashi R, Ishii H, Naito Z, Shimizu A. Morphological spectrum of renal pathology and its correlation to clinical features in patients with disseminated intravascular coagulation: a study involving a series of 21 autopsy cases. Pathol Int. 2014;64:443–52.
Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost. 2007;5:642–5.
Chow KM, Lai FM, Wang AY, Chan YL, Tang NL, Li PK. Reversible renal failure in paroxysmal nocturnal hemoglobinuria. Am J Kidney Dis. 2001;37:1–6.
Puri V, Gandhi A, Sharma S. Renal biopsy in paroxysmal nocturnal hemoglobinuria: an insight into the spectrum of morphologic changes. Indian J Nephrol. 2017;27:284–8.
Ichinoe M, Mikami T, Ujiie S, Suzuki K, Okayasu I. Heparin-induced thrombocytopenia with multiple organized thrombi accompanied by unusual cholesterin deposition: Autopsy case after long-term follow up: Case Report. Pathol Int. 2009;59:757–61.
Sawaki D, Otani Y, Kobayakawa N, Sekita G, Fukushima K, Takeuchi H, et al. A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure first autopsy report on Japan. Circ J. 2004;68:1215–8.
Hermanns B, Janssens U, Handt S, Füzesi L. Pathomorphological aspects of heparin-induced thrombocytopenia II (HIT-II syndrome). Virchows Arch. 1998;432:541–6.
Theuerkauf I, Lickfett L, Harbrecht U, Pohl C, Fischer H, Pfeifer U. Segmental hepatic vein thrombosis associated with heparin-induced thrombocytopenia II. Virchows Arch. 2000;436:88–91.
Althaus K, Möller P, Uzun G, Singh A, Beck A, Bettag M, et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica. 2021;106:2170–9.
Wiedmann M, Skattør T, Stray-Pedersen A, Romundstad L, Antal E-A, Marthinsen PB, et al. Vaccine induced immune thrombotic thrombocytopenia causing a severe form of cerebral venous thrombosis with high fatality rate: a case series. Front Neurol. 2021;12:721146.
Pomara C, Sessa F, Ciaccio M, Dieli F, Esposito M, Garozzo SF, et al. Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica. 2021;106:2291–3.
Roncati L, Manenti A, Corsi L. A three-case series of thrombotic deaths in patients over 50 with comorbidities temporally after modRNA COVID-19 vaccination. Basel: Pathog; 2022. p. 11.
Pomara C, Salerno M, Esposito M, Sessa F, Certo F, Tripodo C, et al. Histological and immunohistochemical findings in a fatal case of thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Pathol Res Pract. 2022;231:153796.
Fanni D, Saba L, Demontis R, Gerosa C, Chighine A, Nioi M, et al. Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature. Eur Rev Med Pharmacol Sci. 2021;25:5063–9.
Mele F, Tafuri S, Stefanizzi P, Amati D, Calvano A, Leonardelli M. M, et al. Cerebral venous sinus thrombosis after COVID-19 vaccination and congenital deficiency of coagulation factors: Is there a correlation? Hum Vaccin Immunother. 2022;2095166.
Bucciarelli S, Cervera R, Espinosa G, Gómez-Puerta JA, Ramos-Casals M, Font J. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors. Autoimmun Rev. 2006;6:72–5.
Bucciarelli S, Espinosa G, Cervera R, Erkan D, Gómez-Puerta JA, Ramos-Casals M, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568–76.
Mizuno R, Fujimoto S, Fujimoto T, Nishino T, Shiiki H, Hashimoto T, et al. Catastrophic antiphospholipid antibody syndrome in systemic lupus erythematosus: An autopsy case report of a young woman. Intern Med. 2000;39:856–9.
Kinjo K, Terabe H, Ogawa M, Takeda H, Cho D, Hoshino S, et al. A case of catastrophic antiphospholipid syndrome presenting with acute respiratory distress syndrome as the initial manifestation. Rheumatol Int. 2008;29:211–6.
Trougakos IP, Terpos E, Alexopoulos H, Politou M, Paraskevis D, Scorilas A, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022;28:542–54.
Kamura Y, Terao T, Akao S, Kono Y, Honma K, Matsue K. Fatal thrombotic microangiopathy with rhabdomyolysis as an initial symptom after the first dose of mRNA–1273 vaccine: A case report. Int J Infect Dis. 2022;117:322–5.
Haslbauer JD, Tzankov A, Mertz KD, Schwab N, Nienhold R, Twerenbold R, et al. Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19. J Pathol Clin Res. 2021;7:326–37.
Vallone MG, Falcón AL, Castro HM, Ferraris A, Cantarella RF, Staneloni MI, et al. Thrombotic events following Covid-19 vaccines compared to Influenza vaccines. Eur J Intern Med. 2022.
Ishizu A, Fukaya S, Tomaru U, Katsumata K, Suzuki A, Umemoto Y, et al. Acute renal failure due to thrombotic microangiopathy in patient with scleroderma: autopsy case report. Ann Vasc Dis. 2012;5:458–61.
Gallan AJ, Chang A. A new paradigm for renal thrombotic microangiopathy. Semin Diagn Pathol. 2020;37:121–6.
Yamada R, Nemoto T, Ohashi K, Tonooka A, Horiguchi S ichiro, Motoi T, et al. Distribution of transplantation-associated thrombotic microangiopathy (TA-TMA) and comparison between renal TA-TMA and intestinal TA-TMA: autopsy study. Biol Blood Marrow Transplant. 2020;26:178–88.
Siami K, Kojouri K, Swisher KK, Selby GB, George JN, Laszik ZG. Thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: An autopsy study. Transplantation. 2008;85:22–8.
Goyama S, Takeuchi K, Kanda Y, Nannya Y, Chiba S, Fukayama M, et al. Post-transplant endothelial disorder after hematopoietic SCT: A blinded autopsy study. Bone Marrow Transplant. 2012;47:1243–5.
Tsokos M, Longauer F, Kardosová V, Gavel A, Anders S, Schulz F. Maternal death in pregnancy from HELLP syndrome. A report of three medico-legal autopsy cases with special reference to distinctive histopathological alterations. Int J Legal Med. 2002;116:50–3.
Zununi Vahed S, Rahbar Saadat Y, Ardalan M. Thrombotic microangiopathy during pregnancy. Microvasc Res. 2021;138:104226.
Tsokos M. Pathological features of maternal death from HELLP syndrome. In: Tsokos M, editor. Forensic Pathology Reviews. Totowa: Humana Press; 2004. pp. 275–90.